Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.

Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?

Bristol-Myers

Gilead Sciences

Johnson & Johnson

Legend Biotech

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

Basel, January 19, 2024 – Novartis today presented data from the Phase III NETTER-2 trial showing that Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose octreotide LAR alone1. Data were presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Novartis (NVS) closed at $108.03 in the latest trading session, marking a -0.21% move from the prior day.

Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You Trade

Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.

Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024

Eli Lilly

As investors, our job isn't to predict an unknowable future.

These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High

The latest trading day saw Novartis (NVS) settling at $107.45, representing a -0.14% change from its previous close.

Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note

Cytokinetics

Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS).  Shares of the biopharmaceutical company have more than doubled since the end of October on speculation of a deal, and on Wednesday the stock closed at $101.63 on speculation that a deal would go through.

Cytokinetics stock plunges as Novartis retreats from merger talks

Novartis has backed away from its pursuit of Cytokinetics , the Wall Street Journal reported on Thursday, citing sources.

Novartis drops pursuit of Cytokinetics - WSJ

Novartis has backed away from its pursuit of Cytokinetics.

Novartis Pursuit of Cytokinetics Cools

Alphabet

iShares Nasdaq Biotechnology ETF

iShares Russell 2000 ETF

Karuna Therapeutics Inc

Microsoft

NVIDIA

Novo Nordisk

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

Bullish Continuation in '24? 3 Market Areas to Watch

Agenus

Compugen

GlaxoSmithKline

iTeos Therapeutics, Inc.

Merck

Pfizer

Arcus Biosciences

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Novartis AG (NVS) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Cytokinetics Inc (NASDAQ: CYTK) popped another 15% on Monday following a report that Novartis AG (SWX: NOVN) is now in advanced talks to acquire the biopharmaceutical firm.

Novartis in advanced talks to buy Cytokinetics

Novartis is closing in on a takeover of Cytokinetics, the Wall Street Journal reported Monday, leading CYTK stock to soar in afternoon action.

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal

Novartis NOVN, +0.43% is close to acquiring Cytokinetics Inc. CYTK, +15.04% and its promising heart drug, according to a Wall Street Journal report Monday. A deal for South San Francisco-based Cytokinetics, which has a market value of about $9 billion, could be finalized as soon as this week, according to people familiar with the situation, the Journal reported.

Novartis, Cytokinetics near merger: report

Swiss drugmaker Novartis is close to acquiring Cytokinetics and the deal could be finalized as soon as this week, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Novartis in advanced talks to buy Cytokinetics- WSJ

Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug.

Novartis in Advanced Talks to Buy Cytokinetics

Voyager Therapeutics

Voyager Therapeutics Inc. NASDAQ: VYGR is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with Novartis AG NYSE: NVS.

Voyager Therapeutics stock pops 30% on deal with Novartis

Alphabet unit Isomorphic Labs, which uses AI to help discover new drugs, entered collaboration deals with Eli Lilly and Novartis.

Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis

Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it's entered into strategic partnerships with two pharmaceutical giants, Eli Lilly and Novartis, to apply AI to discover new medications to treat challenging diseases. The deals have a combined value of around $3 billion.

Isomorphic inks deals with Eli Lilly and Novartis for drug discovery

Amgen

Sanofi

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventive pediatric, adolescent, and adult vaccines The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

7 Rock-Solid Healthcare Dividend Stocks to Buy in January

In the most recent trading session, Novartis (NVS) closed at $106.31, indicating a +0.7% shift from the previous trading day.

Novartis (NVS) Beats Stock Market Upswing: What Investors Need to Know

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?

News for Novartis Stock (NVS)